What is Tedor Pharma?
Tedor Pharma, a US-based contract development and manufacturing organization (CDMO), specializes in the production of solid dose pharmaceuticals and controlled substances. Leveraging over two decades of expertise, the company offers a full spectrum of services, encompassing formulation and process development, analytical support, clinical trial supply, and commercial manufacturing. Their facility, registered with the FDA and licensed by the DEA, ensures adherence to stringent quality and regulatory standards. Tedor Pharma provides adaptable, end-to-end outsourcing solutions for small molecule drug products, catering to a diverse client base.
How much funding has Tedor Pharma raised?
Tedor Pharma has raised a total of $1.9M across 2 funding rounds:
Debt
$1M
Debt
$949K
Debt (2020): $1M with participation from PPP
Debt (2021): $949K led by PPP
Key Investors in Tedor Pharma
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Tedor Pharma?
The recent major strategic investment signals Tedor Pharma's readiness for accelerated growth and potential expansion of its manufacturing capabilities. This capital infusion is likely to bolster its capacity to serve a growing demand for specialized pharmaceutical manufacturing, particularly in controlled substances. The company is well-positioned to deepen its partnerships and potentially explore new service offerings or technological advancements to maintain its competitive edge in the CDMO market.
See full Tedor Pharma company page
